DFTX supply chain intelligence for Definium Therapeutics, Inc.: verified suppliers, customers, debt relationships, acquisitions, and ownership data.
Data compiled by Redley Lamar · ChainSifter Intelligence
Definium Therapeutics, Inc. (DFTX) is shown with relationship data already present in ChainSifter's database. Counts below come from stored supply-chain records and filing/source URLs where available; missing source URLs are not filled in or estimated.
| Ticker | Name | Confidence | Evidence |
|---|---|---|---|
| CONTRACT-MANUFACTURING-ORGANIZATIONS | CONTRACT-MANUFACTURING-ORGANIZATIONS | 90% | the cost of manufacturing products for use in our preclinical studies and clinical trials, including payments to contract manufacturing organizations and consultants |
| CONTRACT-RESEARCH-ORGANIZATIONS | CONTRACT-RESEARCH-ORGANIZATIONS | 90% | payments to third parties in connection with the clinical development of our product candidates, including licensing fees and fees to contract research organizations and consultants |
| THIRD-PARTIES | THIRD-PARTIES | 85% | sponsored research arrangements with third parties |
| ORANY | ORANY | 72% | nes, damages, administrative civil money penalties, and exclusion from participation in federal healthcare programs. • The federal civil False Claims Act, which prohibits anyone from, among other thi… |
| ORANY | ORANY | 72% | Reciprocal relationship from ORANY graph: Reciprocal relationship from DFTX graph: nes, damages, administrative civil money penalties, and exclusion from participation in federal healthcare programs.… |
| TNXP | Tonix Pharmaceuticals Holding Corp. | 72% | Reciprocal relationship from TNXP graph: Reciprocal relationship from DFTX graph: Reciprocal relationship from TNXP graph: arket strategy. Our commercialization strategy for TONMYA is centered on a c… |
| XRTX | XORTX Therapeutics Inc. | 62% | Reciprocal relationship from XRTX graph: ion (2015). Medical degree from University College Hospital Medical School, University of London, with Honors. Raymond Pratt, (2) Maryland, United States 75 D… |
| Ticker | Name | Confidence | Evidence |
|---|---|---|---|
| ORANY | ORANY | 72% | nes, damages, administrative civil money penalties, and exclusion from participation in federal healthcare programs. • The federal civil False Claims Act, which prohibits anyone from, among other thi… |
| ORANY | ORANY | 72% | Reciprocal relationship from ORANY graph: Reciprocal relationship from DFTX graph: Reciprocal relationship from ORANY graph: Reciprocal relationship from DFTX graph: Reciprocal relationship from ORAN… |
| ANKURA-TRUST-COMPANY-LLC | ANKURA-TRUST-COMPANY-LLC | 62% | placements of our common shares and warrants to purchase our common shares, and through our credit facility with K2 HealthVentures LLC (“K2HV”). We incurred net losses of $183.8 million and $108.7 mi… |
| BROADWAY-GOLD-MINING-LTD | BROADWAY-GOLD-MINING-LTD | 62% | , damages, administrative civil money penalties, and exclusion from participation in federal healthcare programs. • The federal civil False Claims Act, which prohibits anyone from, among other things… |
| DEFINIUM-THERAPEUTICS-US-INC | DEFINIUM-THERAPEUTICS-US-INC | 62% | ities ( 151,606 ) — Cash flows from financing activities Proceeds from equity offerings 258,858 249,999 Payment of equity offering costs ( 15,946 ) ( 16,090 ) Proceeds from credit facility 42,000 (1)… |
| DELAWARE-GENERAL-CORPORATION | DELAWARE-GENERAL-CORPORATION | 62% | ivacy and security obligations may require us to notify relevant stakeholders of cybersecurity incidents. Such disclosures are costly, and the disclosures or the failure to comply with such requireme… |
| EMERGING-GROWTH-COMPANY | EMERGING-GROWTH-COMPANY | 62% | ommercialize any product candidates for which we may obtain marketing approval and intend to commercialize on our own or jointly; and • expand our operational, financial and management systems and in… |
| K2-HEALTHVENTURES-LLC | K2-HEALTHVENTURES-LLC | 62% | ities ( 151,606 ) — Cash flows from financing activities Proceeds from equity offerings 258,858 249,999 Payment of equity offering costs ( 15,946 ) ( 16,090 ) Proceeds from credit facility 42,000 (1)… |
| MADISON-METALS-INC-BROADWAY-DELAWARE-SUBCO-INC | MADISON-METALS-INC-BROADWAY-DELAWARE-SUBCO-INC | 62% | , damages, administrative civil money penalties, and exclusion from participation in federal healthcare programs. • The federal civil False Claims Act, which prohibits anyone from, among other things… |
| MIND-MEDICINE-INC | MIND-MEDICINE-INC | 62% | , damages, administrative civil money penalties, and exclusion from participation in federal healthcare programs. • The federal civil False Claims Act, which prohibits anyone from, among other things… |
| NOVO-HOLDINGS | NOVO-HOLDINGS | 62% | ivacy and security obligations may require us to notify relevant stakeholders of cybersecurity incidents. Such disclosures are costly, and the disclosures or the failure to comply with such requireme… |
| Instrument | Description | Confidence | Evidence |
|---|---|---|---|
| DFTX-DEBT | Debt stack $36.5M | 90% | Market cache reports total debt of $36.5M. |
| DFTX-DEBT-9066 | Warrants outstanding: 3767000 | 90% | xbrl warrant detail from xbrl 2025-12-31. |
| Holder | Name | Confidence | Evidence |
|---|---|---|---|
| DFTX-OWNER-AVORO-CAPITAL-ADVISORS-LLC | Avoro Capital Advisors LLC | 90% | 13F overlay lists Avoro Capital Advisors LLC as top holder; 12 tracked holders. |
| Ticker | Name | Chain Index | Hops | Relationship Types |
|---|---|---|---|---|
| AXSM | Axsome Therapeutics, Inc. | 100.00 | 2 | |
| ORANY | ORANGE | 100.00 | 1 | ['customer', 'supplier'] |
| JNJ | Johnson & Johnson | 100.00 | 2 | |
| AZN | AstraZeneca PLC | 100.00 | 2 | |
| DWTX | Dogwood Therapeutics, Inc. | 100.00 | 2 | |
| XRTX | XORTX Therapeutics Inc. | 100.00 | 1 | ['supplier'] |
| D | Dominion Energy, Inc. | 50.00 | 2 | |
| CYCN | Cyclerion Therapeutics, Inc. | 50.00 | 2 | |
| AMZE | Amaze Holdings, Inc. | 50.00 | 2 | |
| CHUC | Charlie's Holdings, Inc. | 50.00 | 2 | |
| CLNE | Clean Energy Fuels Corp. | 50.00 | 2 | |
| FENC | Fennec Pharmaceuticals Inc. | 50.00 | 2 | |
| EQR | Equity Residential | 50.00 | 2 | |
| CANF | Can-Fite BioPharma Ltd. | 50.00 | 2 | |
| AYTU | Aytu BioPharma, Inc. | 50.00 | 2 | |
| ED | Consolidated Edison, Inc. | 50.00 | 2 | |
| ESS | Essex Property Trust, Inc. | 50.00 | 2 | |
| DARE | Daré Bioscience, Inc. | 50.00 | 2 | |
| CORT | Corcept Therapeutics Incorporated | 50.00 | 2 | |
| CNOB | ConnectOne Bancorp, Inc. | 50.00 | 2 |